All content on this page is intended for educational and research purposes only. BPC-157, TB-500, and MGF are not approved by the FDA for human use and are sold exclusively as research compounds.
What Is BPC Wolverine?
BPC Wolverine is a triple-peptide research blend combining BPC-157, TB-500, and MGF (Mechano Growth Factor) in a single lyophilized vial. The combination is sometimes called the Wolverine Stack in research communities, a reference to the way the three compounds target distinct but complementary biological pathways studied in the context of tissue repair, cellular migration, and muscle regeneration.
What makes this combination interesting from a research standpoint is not that any one compound is uniquely powerful. It is that each of the three operates on a different mechanism with minimal pathway overlap. BPC-157 research focuses on angiogenesis and nitric oxide signaling. TB-500 research addresses cytoskeletal dynamics and cell migration. MGF research examines local muscle regeneration through a splice variant of IGF-1. Studying them together allows researchers to examine whether simultaneous modulation of these three pathways produces outcomes different from any single compound in isolation.
All three compounds are classified as research chemicals. None are approved by the FDA for human or veterinary therapeutic use.
The Three Compounds and What the Research Shows
BPC-157: The Most Studied of the Three
BPC-157 is a synthetic 15-amino-acid peptide originally isolated from human gastric juice, where it appears to play a role in maintaining mucosal integrity. It was first characterized by researcher Predrag Sikiric and colleagues at the University of Zagreb in the 1990s and has since accumulated one of the largest preclinical evidence bases of any peptide in this research category, with over 100 published studies across three decades.
The most consistently documented mechanism involves vascular endothelial growth factor receptor 2 (VEGFR2) activation. A 2017 study published in the Journal of Molecular Medicine by Hsieh et al. demonstrated that BPC-157 promotes VEGFR2 internalization alongside VEGFR2-Akt-eNOS activation, increasing vessel density in both in vivo and in vitro models. This angiogenic mechanism is significant for connective tissue research because tendons, ligaments, and other musculoskeletal structures are inherently poorly vascularized. Inadequate blood supply is considered a primary rate-limiting factor in their repair.
A second mechanism involves nitric oxide modulation. A 2020 study published in Scientific Reports (PMC7555539) documented that BPC-157 activates endothelial nitric oxide synthase through VEGFR2 activation, AKT stimulation, and reduction of the Caveolin-1 inhibitory interaction with eNOS. The finding that BPC-157 modulates nitric oxide bidirectionally rather than simply elevating it distinguishes it mechanistically from standard angiogenic compounds.
A third pathway involves fibroblast behavior. A study published in the Journal of Applied Physiology (DOI: 10.1152/japplphysiol.00945.2010) found that BPC-157 markedly increased fibroblast survival under oxidative stress and enhanced fibroblast migration in a dose-dependent manner. These effects were linked to tendon outgrowth and cellular repair rather than direct proliferative stimulation.
A 2025 systematic review in the American Journal of Sports Medicine by Vasireddi et al. examined the full BPC-157 literature from an orthopedic sports medicine perspective. Of 544 research articles screened, the review confirmed preclinical support across tendon, ligament, muscle, and bone repair models. It was also explicit that human clinical trial data for musculoskeletal applications is essentially nonexistent. The entire evidence base for these applications comes from animal models, primarily rodents.
TB-500: The Actin Dynamics Compound
TB-500 is a synthetic analog of Thymosin Beta-4, a naturally occurring protein found in virtually all human cells that plays a central role in regulating actin, one of the primary structural proteins involved in cell shape, movement, and division. TB-500 was developed as a more stable and more bioavailable form of the active region of Thymosin Beta-4.
Its primary mechanism involves promoting actin polymerization, the process by which actin monomers are assembled into the filaments that form the cellular cytoskeleton. This regulation of cytoskeletal dynamics drives cell migration, the ability of cells to move through tissue. That movement is essential at injury sites where repair cells need to reach damaged areas. Research published in the Annals of the New York Academy of Sciences by Goldstein and Kleinman documented Thymosin Beta-4’s role in promoting cell migration and angiogenesis, establishing the mechanistic foundation for TB-500’s research applications.
In animal models of wound healing, TB-500 has been studied for its effects on keratinocyte and endothelial cell migration, collagen deposition, and inflammatory modulation. Its mechanism differs meaningfully from BPC-157. Where BPC-157 research focuses primarily on vascular formation and nitric oxide signaling, TB-500 research addresses the cellular movement and matrix dynamics that precede and accompany vascular remodeling.
As of 2026, no published human clinical trials exist for TB-500. All evidence is preclinical.
MGF: The Third Pathway
MGF, or Mechano Growth Factor, is a splice variant of IGF-1 that is produced locally in muscle tissue in response to mechanical strain. It differs from standard IGF-1 in a meaningful way. MGF contains a unique 24-amino-acid E-domain at its C-terminus that is not present in systemic IGF-1. This E-domain is associated with local tissue signaling and satellite cell activation, the process by which dormant muscle stem cells are recruited to repair damaged muscle fibers.
Research by Yang and Goldspink published in FEBS Letters (DOI: 10.1016/S0014-5793(03)00698-6) documented MGF’s distinct behavior from systemic IGF-1, establishing that the E-domain peptide activates satellite cells through a pathway independent of the standard IGF-1 receptor signaling cascade. This means MGF can trigger local muscle regeneration signaling without the systemic effects associated with IGF-1 elevation, a property that makes it useful as a research tool for studying local versus systemic growth factor signaling.
MGF’s addition to the BPC Wolverine blend addresses a biological pathway that neither BPC-157 nor TB-500 directly targets. BPC-157 and TB-500 are primarily studied in connective tissue contexts like tendons, ligaments, and wound healing. MGF is studied specifically in skeletal muscle regeneration. Together, the three compounds allow researchers to examine repair and regeneration across different tissue compartments simultaneously.
As with TB-500, no published human clinical trials exist for MGF as of 2026. All evidence is preclinical.
Why the Combination Is Studied Together
The mechanistic rationale for studying BPC-157, TB-500, and MGF together is straightforward. The three compounds operate on distinct but complementary pathways with minimal overlap.
BPC-157 addresses vascular formation and nitric oxide regulation, the blood supply infrastructure that delivers oxygen and nutrients to repair sites. TB-500 addresses cellular migration dynamics, the movement of repair cells to injury sites through cytoskeletal regulation. MGF addresses local muscle regeneration signaling, the activation of satellite cells that rebuild damaged muscle fibers.
A repair or regeneration research model that only addresses one of these pathways is studying an incomplete picture. Researchers studying the Wolverine Stack examine whether targeting all three simultaneously changes experimental outcomes compared to any single compound alone. The hypothesis is additive or synergistic activity across the three pathways, though no controlled human trials have evaluated this combination directly.
Where the Human Research Stands in 2026
For BPC-157, the published human data as of 2026 consists of three small studies totaling fewer than 30 participants. A 2021 knee pain study (16 patients) reported significant pain relief in 87.5% of participants following intra-articular injection, with no control group. A 2024 interstitial cystitis study (12 patients) by Lee et al. reported complete symptom resolution in 10 of 12 participants following intravesical injection of 10mg BPC-157, with no adverse events. A 2025 IV safety study involving 2 adults found up to 20mg IV tolerated with no adverse effects and plasma levels returning to baseline within 24 hours.
Worth noting: all three studies came from the same Florida research group, none had placebo controls, and a 2015 Phase I trial that enrolled 42 volunteers was cancelled in 2016 with zero published results. Dosing protocols used in research today are extrapolated from animal models, not human pharmacokinetic data.
For TB-500 and MGF, no published human clinical trials exist as of 2026. The entire evidence base for both compounds is preclinical.
Purity and Quality Documentation
Every batch of Alpha Peps BPC Wolverine is independently tested by Freedom Diagnostics, a USA-based laboratory. Testing is conducted using LCMS/MS under standard laboratory conditions. The current batch (Lot 26243, received February 23, 2026) returned a purity of 99.717%, with endotoxin testing passing both replicates per USP <85> Bacterial Endotoxins standard. COA numbers 2602230054 and 2602230055 are searchable directly at FreedomDiagnosticsTesting.com.
The batch-specific COA is included with every order, meaning the documentation matches the exact vial received rather than a generic product-level certificate.
View the BPC Wolverine product page, full composition details, and COA documentation here.
What We Don’t Know Yet
The honest picture on this research stack requires acknowledging what the evidence does and does not support.
No human trial data exists for the combination. Every finding discussed on this page comes from studies of individual compounds in animal models. No controlled research has evaluated BPC-157, TB-500, and MGF together in human subjects.
Animal-to-human translation is unvalidated. Over 100 preclinical BPC-157 studies across three decades represent a meaningful evidence base. They do not constitute validated human efficacy. The gap between consistent animal findings and confirmed human outcomes is real and documented across peptide research broadly.
Regulatory status. BPC-157 is classified as a Category 2 bulk drug substance, restricting compounding pharmacy access in the United States. TB-500 and MGF are unapproved research compounds. None of the three are approved for human or veterinary therapeutic use by any regulatory agency worldwide.
WADA classification. BPC-157 was added to the World Anti-Doping Agency prohibited substance list in 2022 under category S0: Non-Approved Substances. Researchers working in sports science contexts should note this classification.
Frequently Asked Questions
What is in BPC Wolverine?
BPC Wolverine contains three synthetic research peptides in a single lyophilized vial: BPC-157 (11.03mg), TB-500 (2.62mg), and MGF Peptide (1.10mg). Composition is verified by batch-specific third-party COA from Freedom Diagnostics, USA.
How is BPC Wolverine different from just BPC-157 or TB-500 alone?
BPC-157 and TB-500 are each studied for distinct mechanisms. BPC-157 for angiogenesis and nitric oxide signaling, TB-500 for actin dynamics and cell migration. MGF adds a third pathway targeting local muscle regeneration through satellite cell activation, which neither BPC-157 nor TB-500 directly addresses. The combination allows researchers to examine all three pathways simultaneously in a single experimental model.
Is there human research on BPC Wolverine as a combination?
No. No published human trials have evaluated BPC-157, TB-500, and MGF together. The three small human studies that exist cover BPC-157 only, in separate indications, with no placebo controls. For TB-500 and MGF, no human clinical trial data exists as of 2026.
What is the purity of Alpha Peps BPC Wolverine?
The current batch (Lot 26243, tested February 2026) returned 99.717% purity confirmed by HPLC with UV Detection and Mass Spectrometry, plus endotoxin pass on both replicates per USP <85> standard. COA numbers 2602230054 and 2602230055 are searchable at FreedomDiagnosticsTesting.com.
What is MGF and why is it in the blend?
MGF, or Mechano Growth Factor, is a splice variant of IGF-1 produced locally in muscle tissue in response to mechanical strain. It activates satellite cells through a pathway independent of standard IGF-1 receptor signaling. Its inclusion in the BPC Wolverine blend adds a muscle regeneration signaling component that BPC-157 and TB-500 do not directly target.
Where can I source BPC Wolverine for research?
Alpha Peps supplies research-grade BPC Wolverine (10/2.5/1mg) with batch-specific third-party COA verification, 99.7%+ purity, and endotoxin clearance. All products are for laboratory research use only and are not intended for human consumption.
This article is for informational and research purposes only. Nothing on this page constitutes medical advice. BPC-157, TB-500, and MGF are not approved for human use and should only be handled by qualified researchers in appropriate laboratory settings.
